Metabolic Acidosis
By:
Zhabiz Solhjou Renal Division, Brigham and Women’s Hospital, Boston, Massachusetts

Search for other papers by Zhabiz Solhjou in
Current site
Google Scholar
PubMed Close
and
Martina M. McGrath Renal Division, Brigham and Women’s Hospital, Boston, Massachusetts
Renal Division, Veterans Affairs Boston Healthcare System, Boston, Massachusetts

Search for other papers by Martina M. McGrath in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 20: Issue 2
Published Online:
Jan 2022
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand

Volume 20: Issue 2 (Jan 2022): Electrolytes and Acid-Base Disorders

in Nephrology Self-Assessment Program
Cover Nephrology Self-Assessment Program
Copyright:
Copyright © 2022 by the American Society of Nephrology 2022
Page Count:
15
Article Category:
Research Article
Print Publication Date:
01 Jan 2022
Published Online:
Jan 2022
  • 1

    Seifter JL, Chang H-Y: Extracellular acid-base balance and ion transport between body fluid compartments. Physiology (Bethesda) 32: 367–379, 2017 PubMed

  • 2

    Matyukhin I, Patschan S, Ritter O, Patschan D: Etiology and management of acute metabolic acidosis: An update. Kidney Blood Press Res 45: 523–531, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    Kraut JA, Madias NE: Re-evaluation of the normal range of serum total CO2 concentration. Clin J Am Soc Nephrol 13: 343–347, 2018 PubMed

  • 4

    Kraut JA, Madias NE: Serum anion gap: Its uses and limitations in clinical medicine. Clin J Am Soc Nephrol 2: 162–174, 2007 PubMed

  • 5

    Sun S, Li H, Chen J, Qian Q: Lactic acid: No longer an inert and end-product of glycolysis. Physiology (Bethesda) 32: 453–463, 2017 PubMed

  • 6

    Meyer C, Stumvoll M, Dostou J, Welle S, Haymond M, Gerich J: Renal substrate exchange and gluconeogenesis in normal postabsorptive humans. Am J Physiol Endocrinol Metab 282: E428–E434, 2002 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    Husain Z, Huang Y, Seth P, Sukhatme VP: Tumor-derived lactate modifies antitumor immune response: Effect on myeloid-derived suppressor cells and NK cells. J Immunol 191: 1486–1495, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8

    Errea A, Cayet D, Marchetti P, Tang C, Kluza J, Offermanns S, et al.: Lactate inhibits the pro-inflammatory response and metabolic reprogramming in murine macrophages in a GPR81-independent manner. PLoS One 11: e0163694, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9

    Kraut JA, Madias NE: Lactic acidosis. N Engl J Med 371: 2309–2319, 2014 PubMed

  • 10

    Rudkin SE, Grogan TR, Treger RM: The Δ anion gap/Δ bicarbonate ratio in early lactic acidosis: Time for another delta? https://kidney360.asnjournals.org/content/2/1/20. Kidney360 2: 20–25, 2020

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11

    Kraut JA, Madias NE: Lactic acidosis: Current treatments and future directions. Am J Kidney Dis 68: 473–482, 2016 PubMed

  • 12

    Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M: Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 308: 1566–1572, 2012 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Raghunathan K, Bonavia A, Nathanson BH, Beadles CA, Shaw AD, Brookhart MA, et al.: Association between initial fluid choice and subsequent in-hospital mortality during the resuscitation of adults with septic shock. Anesthesiology 123: 1385–1393, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Semler MW, Self WH, Wanderer JP, Ehrenfeld JM, Wang L, Byrne DW, et al.; SMART Investigators and the Pragmatic Critical Care Research Group: Balanced crystalloids versus saline in critically ill adults. N Engl J Med 378: 829–839, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15

    Self WH, Semler MW, Wanderer JP, Wang L, Byrne DW, Collins SP, et al.; SALT-ED Investigators: Balanced crystalloids versus saline in noncritically ill adults. N Engl J Med 378: 819–828, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    Palevsky PM: Intravenous fluids: Finding the right balance. Clin J Am Soc Nephrol 13: 1912–1914, 2018

  • 17

    Self WH, Evans CS, Jenkins CA, Brown RM, Casey JD, Collins SP, et al.; Pragmatic Critical Care Research Group: Clinical effects of balanced crystalloids vs saline in adults with diabetic ketoacidosis: A subgroup analysis of cluster randomized clinical trials. JAMA Netw Open 3: e2024596, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18

    Group KDIGO; Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group: KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98[4S]: S1–S115, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19

    Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al.: Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65: 1190–1195, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20

    Palmer BF, Clegg DJ: Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy. Clin J Am Soc Nephrol 16: 1284–1291, 2021 PubMed

  • 21

    Erondu N, Desai M, Ways K, Meininger G: Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 38: 1680–1686, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22

    Rosenstock J, Ferrannini E: Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38: 1638–1642, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23

    Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB: Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38: 1687–1693, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24

    Kum-Nji JS, Gosmanov AR, Steinberg H, Dagogo-Jack S: Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management. J Diabetes Complications 31: 611–614, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25

    Vitale RJ, Valtis YK, McDonnell ME, Palermo NE, Fisher NDL: euglycemic diabetic ketoacidosis with COVID-19 infection in patients with type 2 diabetes taking SGLT2 inhibitors. AACE Clin Case Rep 7: 10–13, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26

    Donnan K, Segar L: SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol 846: 23–29, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27

    Ting S, Chua H-R, Cove ME: Euglycemic ketosis during continuous kidney replacement therapy with glucose-free solution: A report of 8 cases. Am J Kidney Dis 78: 305–308, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28

    Farese S, Stauffer E, Kalicki R, Hildebrandt T, Frey BM, Frey FJ, et al.: Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers. Clin J Am Soc Nephrol 6: 1447–1455, 2011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29

    Jiang J, Chan A, Ali S, Saha A, Haushalter KJ, Lam WL, et al.: Hydrogen sulfide--mechanisms of toxicity and development of an antidote. Sci Rep 6: 20831, 2016 PubMed

  • 30

    Hundemer GL, Fenves AZ, Phillips KM, Emmett M: Sodium thiosulfate and the anion gap in patients treated by hemodialysis. Am J Kidney Dis 68: 499–500, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31

    Rein JL, Miyata KN, Dadzie KA, Gruber SJ, Sulica R, Winchester JF: Successfully treated calcific uremic arteriolopathy: Two cases of a high anion gap metabolic acidosis with intravenous sodium thiosulfate. Case Rep Nephrol 2014: 765134, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32

    Mao M, Lee S, Kashani K, Albright R, Qian Q: Severe anion gap acidosis associated with intravenous sodium thiosulfate administration. J Med Toxicol 9: 274–277, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33

    Mariano F, Biancone L: Metformin, chronic nephropathy and lactic acidosis: A multi-faceted issue for the nephrologist. J Nephrol 34: 1127–1135, 2021 PubMed

  • 34

    Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al.: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49: 2063–2069, 2000 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35

    DeFronzo R, Fleming GA, Chen K, Bicsak TA: Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism 65: 20–29, 2016 PubMed

  • 36

    Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al.: Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510: 542–546, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37

    Alvarez CA, Halm EA, Pugh MJV, McGuire DK, Hennessy S, Miller RT, et al.: Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study. Endocrinol Diabetes Metab 4: e00170, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38

    Boucaud-Maitre D, Ropers J, Porokhov B, Altman JJ, Bouhanick B, Doucet J, et al.: Lactic acidosis: Relationship between metformin levels, lactate concentration and mortality. Diabet Med 33: 1536–1543, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39

    Pham AQT, Xu LHR, Moe OW: Drug-induced metabolic acidosis. F1000Res 4: F1000, 2015 PubMed

  • 40

    Calello DP, Liu KD, Wiegand TJ, Roberts DM, Lavergne V, Gosselin S, et al.; Extracorporeal Treatments in Poisoning Workgroup: Extracorporeal treatment for metformin poisoning: Systematic review and recommendations from the Extracorporeal Treatments in Poisoning Workgroup. Crit Care Med 43: 1716–1730, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41

    Madias NE: Metabolic acidosis and CKD progression. Clin J Am Soc Nephrol 16: 310–312, 2021

  • 42

    Raphael KL: Metabolic acidosis and subclinical metabolic acidosis in CKD. J Am Soc Nephrol 29: 376–382, 2018 PubMed

  • 43

    Raphael KL, Zhang Y, Ying J, Greene T: Prevalence of and risk factors for reduced serum bicarbonate in chronic kidney disease. Nephrology (Carlton) 19: 648–654, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44

    Kidney Disease: Improving Global Outcomes. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Available at: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf. Accessed October 31, 2021

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45

    Gennari FJ, Hood VL, Greene T, Wang X, Levey AS: Effect of dietary protein intake on serum total CO2 concentration in chronic kidney disease: Modification of Diet in Renal Disease study findings. Clin J Am Soc Nephrol 1: 52–57, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46

    Chen W, Levy DS, Abramowitz MK: Acid base balance and progression of kidney disease. Semin Nephrol 39: 406–417, 2019 PubMed

  • 47

    Goraya N, Simoni J, Sager LN, Mamun A, Madias NE, Wesson DE: Urine citrate excretion identifies changes in acid retention as eGFR declines in patients with chronic kidney disease. Am J Physiol Renal Physiol 317: F502–F511, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48

    Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, et al.: Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 77: 617–623, 2010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49

    Driver TH, Shlipak MG, Katz R, Goldenstein L, Sarnak MJ, Hoofnagle AN, et al.: Low serum bicarbonate and kidney function decline: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 64: 534–541, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50

    Gardner J, Tuttle K, Raphael KL: Influence of medications containing acid salts on serum bicarbonate in CKD. Kidney360 1: 330–336, 2020

  • 51

    Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, et al.; NephroTest Study Group: Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 20: 164–171, 2009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52

    Goraya N, Simoni J, Sager LN, Madias NE, Wesson DE: Urine citrate excretion as a marker of acid retention in patients with chronic kidney disease without overt metabolic acidosis. Kidney Int 95: 1190–1196, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53

    Shah SN, Abramowitz M, Hostetter TH, Melamed ML: Serum bicarbonate levels and the progression of kidney disease: A cohort study. Am J Kidney Dis 54: 270–277, 2009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54

    Menon V, Tighiouart H, Vaughn NS, Beck GJ, Kusek JW, Collins AJ, et al.: Serum bicarbonate and long-term outcomes in CKD. Am J Kidney Dis 56: 907–914, 2010 PubMed

  • 55

    Dobre M, Yang W, Pan Q, Appel L, Bellovich K, Chen J, et al.; CRIC Study Investigators: Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Heart Assoc 4: e001599, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56

    Wesson DE, Buysse JM, Bushinsky DA: Mechanisms of metabolic acidosis–induced kidney injury in chronic kidney disease. J Am Soc Nephrol 31: 469–482, 2020

  • 57

    Kohan DE, Barton M: Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 86: 896–904, 2014 PubMed

  • 58

    Wesson DE, Simoni J, Broglio K, Sheather S: Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. Am J Physiol Renal Physiol 300: F830–F837, 2011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59

    Nath KA, Hostetter MK, Hostetter TH: Increased ammoniagenesis as a determinant of progressive renal injury. Am J Kidney Dis 17: 654–657, 1991 PubMed

  • 60

    Nath KA, Hostetter MK, Hostetter TH: Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 76: 667–675, 1985 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61

    Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE: Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 78: 303–309, 2010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62

    Di Iorio BR, Bellasi A, Raphael KL, Santoro D, Aucella F, Garofano L, et al.; UBI Study Group: Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: The UBI Study. J Nephrol 32: 989–1001, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63

    Raphael KL, Isakova T, Ix JH, Raj DS, Wolf M, Fried LF, et al.: A randomized trial comparing the safety, adherence, and pharmacodynamics profiles of two doses of sodium bicarbonate in CKD: The BASE Pilot Trial. J Am Soc Nephrol 31: 161–174, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64

    Navaneethan SD, Shao J, Buysse J, Bushinsky DA: Effects of treatment of metabolic acidosis in CKD: A systematic review and meta-analysis. Clin J Am Soc Nephrol 14: 1011–1020, 2019

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65

    Witham MD, et al.; BiCARB study group: Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): A pragmatic randomised, double-blind, placebo-controlled trial. BMC Med 18: 91, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66

    Kendrick J, Shah P, Andrews E, You Z, Nowak K, Pasch A, et al.: Effect of treatment of metabolic acidosis on vascular endothelial function in patients with CKD: A pilot randomized cross-over study. Clin J Am Soc Nephrol 13: 1463–1470, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67

    Clegg DJ, Gallant KMH: Plant-based diets in CKD. Clin J Am Soc Nephrol 14: 141–143, 2019

  • 68

    Brady C, Chemaly ER, Lohr JW, Parker MD: Veverimer: An advance in base therapy for metabolic acidosis. Ann Transl Med 8: 1331, 2020 PubMed

  • 69

    Bushinsky DA, Hostetter T, Klaerner G, Stasiv Y, Lockey C, McNulty S, et al.: Randomized, controlled trial of TRC101 to increase serum bicarbonate in patients with CKD. Clin J Am Soc Nephrol 13: 26–35, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70

    Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, et al.: Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: A multicentre, randomised, double-blind, controlled, phase 3 trial. Lancet 393: 1417–1427, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71

    Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, et al.: Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: A multicentre, randomised, blinded, placebo-controlled, 40-week extension. Lancet 394: 396–406, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72

    Messa PG, Alfieri C, Vettoretti S: Metabolic acidosis in renal transplantation: Neglected but of potential clinical relevance. Nephrol Dial Transplant 31: 730–736, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73

    Ritter A, Mohebbi N: Causes and consequences of metabolic acidosis in patients after kidney transplantation. Kidney Blood Press Res 45: 792–801, 2020 PubMed

  • 74

    Park S, Kang E, Park S, Kim YC, Han SS, Ha J, et al.: Metabolic acidosis and long-term clinical outcomes in kidney transplant recipients. J Am Soc Nephrol 28: 1886–1897, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75

    Gojowy D, Skiba K, Bartmanska M, Kolonko A, Wiecek A, Adamczak M: Is metabolic acidosis a novel risk factor for a long-term graft survival in patients after kidney transplantation? Kidney Blood Press Res 45: 702–712, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76

    Djamali A, Singh T, Melamed ML, Stein JH, Aziz F, Parajuli S, et al.: Metabolic acidosis 1 year following kidney transplantation and subsequent cardiovascular events and mortality: An observational cohort study. Am J Kidney Dis 73: 476–485, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77

    Roberts RJ, Barletta JF, Fong JJ, Schumaker G, Kuper PJ, Papadopoulos S, et al.: Incidence of propofol-related infusion syndrome in critically ill adults: A prospective, multicenter study. Crit Care 13: R169, 2009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78

    Cervantes CE, Menez S, Monroy Trujillo JM, Hanouneh M: Clinical approach to a patient with an acid-base disturbance. Am J Kidney Dis 77: A9–A11, 2021 PubMed

  • 79

    Berns JS, Kasbekar N: Highly active antiretroviral therapy and the kidney: An update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 1: 117–129, 2006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80

    Morales A, Danziger J: Management consideration in drug-induced lactic acidosis. Clin J Am Soc Nephrol 15: 1511–1512, 2020 PubMed

  • 81

    Zand Irani A, Almuwais A, Gibbons H: Acquired pyroglutamic acidosis due to long-term dicloxacillin and paracetamol use. BMJ Case Rep 13: e233306, 2020 PubMed

  • 82

    Poirier-Blanchette L, Simard C, Schwartz BC: Spurious point-of-care lactate elevation in ethylene glycol intoxication: Rediscovering a clinical pearl. BMJ Case Rep 14: e239936, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83

    Patel AR, Nagalli S: Valproate Toxicity. [Updated 2021 Jul 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK560898/. Accessed October 31, 2021

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84

    Juurlink DN, Gosselin S, Kielstein JT, Ghannoum M, Lavergne V, Nolin TD, et al.; EXTRIP Workgroup: Extracorporeal treatment for salicylate poisoning: Systematic review and recommendations from the EXTRIP Workgroup. Ann Emerg Med 66: 165–181, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 441 231 22
Full Text Views 785 407 28
PDF Downloads 1029 542 43